|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cnull mice through cell fusionDepartment of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and the Central Institute for Experimental Animals, Kawasaki, Japan
1Correspondence: Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E-mail: tnakaha{at}kuhp.kyoto-u.ac.jp
| ABSTRACT |
|---|
|
|
|---|
cnull (NOG) mouse model that can achieve a tremendously high level of chimerism when transplanted with human hematopoietic cells. Even without hepatotoxic treatment other than irradiation, human albumin and
-1-antitrypsin-positive cells were invariably detected in the livers of NOG mice after i.v. transplantation of human cord blood CD34+ cells. Human albumin was detected in the murine sera, indicating functional maturation of the human hepatocytes. Flow cytometric analysis of recipient liver cells in single-cell suspension demonstrated that human albumin-positive cells were also positive for both murine and human MHC and were negative for human CD45. PCR analysis of recipient livers revealed the expression of a wide variety of human hepatocyte- or cholangiocyte-specific mRNAs. These results show that human CD34+ cells fuse with hepatocytes of NOG mice without liver injury, lose their hematopoietic phenotype, and begin hepatocyte-specific gene transcription. These phenomena were not observed when CD34– cells were transplanted. Thus, our model revealed a previously unidentified pathway of human hematopoietic stem/progenitor cell differentiation.—Fujino, H., Hiramatsu, H., Tsuchiya, A., Niwa, A., Noma, H., Shiota, M., Umeda, K., Yoshimoto, M., Ito, M., Heike, T., Nakahata, T. Human cord blood CD34+ cells develop into hepatocytes in the livers of NOD/SCID/
cnull mice through cell fusion.
Key Words: liver regeneration hematopoietic stem/progenitor cell mature hepatocyte bone marrow-derived cell
| INTRODUCTION |
|---|
|
|
|---|
Recent studies of mice have revealed a new liver-regenerating cell type, namely, bone marrow cells. In 2000, Lagasse et al. (2)
first showed that i.v. injection of purified bone marrow hematopoietic stem cells (c-kithighThylowLin–Sca-1+ cells) into mice with a lethal fumarylacetoacetate hydrolase (FAH) deficiency rescued the recipients by restoring the biochemical function of their livers; on the basis of this, they proposed the notion of "transdifferentiation," or the differentiation of hematopoietic stem cells into nonhematopoietic cells. However, in 2002 this concept of plasticity was challenged by Terada et al. (3)
and Ying et al. (4)
, when they found that adult stem cells spontaneously fused with embryonic stem cells and took on their characteristics; these authors concluded that "cell fusion" was the mechanism of nonhematopoietic cell generation from hematopoietic cells. Studies in 2003 by Wang et al. (5)
, Vassilopoulos et al. (6)
, and Alvarez-Dolado et al. (7)
supported the cell fusion hypothesis. However, Jang et al. (8)
and Harris et al. (9)
reported in 2004 that hepatocytes that differentiate from bone marrow-derived cells are not the result of cell fusion. In the same year, Willenbring et al. (10)
and Camargo et al. (11)
showed that hematopoietic myelomonocytic-committed cells such as macrophages are the major source of hepatocyte fusion partners. Thus, it remains unclear whether transdifferentiation or cell fusion is the main mechanism that generates hepatocytes from hematopoietic cells.
In humans, Alison et al. (12)
and Theise et al. (13)
showed that the adult human hematopoietic stem cell population can yield hepatocytes upon instruction by the appropriate environment. Korbling et al. (14)
showed that hepatocytes are generated from the bone marrow of recipients of sex-mismatched bone marrow transplants at a high frequency that ranges from 4% to 7%. Moreover, Ng et al. (15)
found that in human liver allografts, although most of the recipient-derived cells showed macrophage/Kupffer cell differentiation, recipient-derived hepatocytes were also present and constituted 0.62% of all the hepatocytes in the recipient.
To examine the mechanisms by which human hematopoietic cells contribute to liver regeneration, the human-to-mouse xenogeneic transplantation model was used. Several reports have shown that when human cord blood (CB) cells (all cells, CD34+ cells, or CD45+ cells) are injected into mice through either the portal vein or the systemic circulation, they can form human hepatocyte-like cells in the murine liver environment (16
17
18
19
20
21
22
23)
. However, even when there is massive liver damage, the frequency with which this hepatocytic differentiation occurs is low compared to that reported in human-to-human transplantation studies. This low level of efficiency makes it hard to clarify whether transdifferentiation or cell fusion is the primary mechanism that generates hepatocytes from human hematopoietic cells. Many attempts have been made to establish more suitable models but have met with limited success.
We postulated that the failure to achieve substantial hepatic chimerism in standard mouse models is due to 1) the low frequency of human hematopoietic cells combined with 2) the intrinsic immune barrier of the murine liver, which will mask the true regenerating potential of human hematopoietic cells. We previously reported that the NOD/SCID/
cnull mouse model provided far better human hematopoietic stem cell engraftment than did NOD/SCID and NOD/SCID/ß2mnull mice (24
25
26)
. NOD/SCID/
cnull mice completely lack natural killer (NK) cell activity and have dendritic cell dysfunction (24)
. Notably, functional human T, NK, and mast cells have been generated and matured from human hematopoietic stem cells in NOD/SCID/
cnull mice (25
, 26)
.
Here we have used the NOD/SCID/
cnull mouse model to address questions about the regeneration of the liver from transplanted human hematopoietic stem cells. First, we asked whether human CB CD34+ cells could develop into functional hepatic and cholangitic cells in the murine liver environment. Second, we asked whether the generation of hepatocytes is due to transdifferentiation or cell fusion. Third, we examined the status of human liver-specific gene transcription in the murine liver. Finally, we investigated whether CD34– cells also have the ability to produce hepatocytes. Our model proved suitable for answering these questions and revealed a previously unidentified pathway of human CD34+ cell differentiation under steady-state conditions.
| MATERIALS AND METHODS |
|---|
|
|
|---|
cnull mice were generated at the Central Institute for Experimental Animals (Kawasaki, Japan), shipped to the animal facility of Kyoto University (Kyoto, Japan), and handled with humane care under pathogen-free conditions. All experiments in this study were performed in accordance with the Animal Protection Guidelines of Kyoto University.
Cell preparation and transplantation protocol
Human CB CD34+ cells were purified using a described method (25)
. Briefly, after we obtained informed consent from the donors parents, we collected mononuclear cells from human CB by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation. The CD34+ fraction was then isolated by using auto-MACS (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) with the "posseld2" program according to the manufacturers recommendations. The "depl 05" and "possel" programs were added to get the CD34– fraction and the CD34–CD14+/– fraction, respectively; this yielded highly pure populations. Eight- to 12-wk-old NOD/SCID/
cnull mice were irradiated with 240cGy, and human CB CD34+ cells (2x104 or 1x105) or CD34–CD14+/– cells (1x107) were injected through the tail vein. Neomycin sulfate (Invitrogen, Carlsbad, CA, USA) in acidic water was supplied to irradiated recipient mice after transplantation.
Flow cytometric analysis of peripheral blood from mice transplanted with human cells
The peripheral blood of mice was collected and transferred to ethylenediaminetetraacetic acid (EDTA) -2Na-containing CAPIJECT (Terumo Medical, Somerset, NJ, USA). The cells were then analyzed by flow cytometry (FACS caliber; BD PharMingen, San Diego, CA, USA) to measure the frequencies of various human hematopoietic cell types using the following antibodies (all purchased from BD PharMingen): fluorescein isothiocyanate- (FITC) and phycoerythrin- (PE) conjugated mouse anti-human CD3, CD4, CD8, CD14, CD19, CD33, CD45, and CD56, and allophycocyanin (APC)-conjugated rat anti-mouse CD45.
Detection of human CB-derived cells in the murine liver by immunohistochemical analysis
Mice were anesthetized, killed by cervical dislocation, and their livers were collected, fixed in 10% formalin, and embedded in paraffin blocks. Four-micrometer sections were cut and placed on silane-coated slides. After removing the paraffin with xylene, the tissue sections were rehydrated with graded alcohol, washed with water, and incubated with primary antibodies diluted with phosphate-buffered saline (PBS) or PBS containing 1% bovine serum albumin. The antibodies (and dilutions) used were rabbit anti-human albumin (1:100) (DAKO Carpinteria, CA, USA), mouse anti-human-specific hepatocyte antigen (HepPar1) (1:100) (DAKO), rabbit anti-human
-1-antitrypsin (1:100) (Neomarkers, Fremont, CA, USA), mouse anti-human CD45 (1:100) (DAKO), mouse anti-human CD68 (1:100) (DAKO), mouse anti-human mitochondria (1:100) (Chemicon International, Inc., Temecula, CA, USA), and rabbit anti-human c-met (1:100) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). All antibodies except for rabbit anti-human c-met were confirmed to be specific for the relevant human antigen by immunohistochemical assays using mouse control specimens (including those from irradiated mice). Three hours incubation at room temperature or an overnight incubation at 4°C was followed by incubation with the 1:100-diluted secondary antibodies: Cy3-conjugated donkey anti-mouse IgG, FITC-conjugated donkey anti-rabbit IgG, peroxidase-conjugated donkey anti-mouse, and peroxidase-conjugated donkey anti-rabbit IgG (all purchased from Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Hoechst 33324 (Molecular Probes, Eugene, OR, USA) was used for nuclear staining. Endogenous peroxidase activity was blocked by application of 3% hydrogen peroxide for 5 min at room temperature and a DAB Substrate Kit (Vector Laboratories, Burlingame, CA, USA) was used for visualization. Antigen retrieval was performed by heating the sections in 10 mM citrate or 10 mM citrate/2 mM EDTA buffer in an autoclave oven for 5 min. These prepared samples were then examined under a light or fluorescent microscope (Olympus, Tokyo, Japan).
Serum human albumin enzyme-linked immunosorbent assay (ELISA)
Peripheral blood was collected into serum separator tubes (BD PharMingen) at various points after transplantation for the human serum albumin assays, and ELISA was performed according to the manufacturers instructions (Cygnus Technologies, Plainville, MA, USA).
Flow cytometric analysis of single liver cells obtained by collagenase perfusion
Mice were anesthetized, their abdomens were opened, and their inferior vena cava was cannulated. The hepatic vein and whole liver were then retrogradely perfused gently at 37°C with Hanks buffered salt solution (HBSS; Gibco BRL, Grand Island, NY, USA) containing 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) at a final concentration of 10 mM (Nakalai Tesque, Inc., Kyoto, Japan) and ethyleneglycoltetraacetic acid at a final concentration of 0.5 mmol/l. This was followed by perfusion with HBSS containing HEPES (final concentration of 10 mM) and collagenase D (final concentration of 200 µg/ml) (Roche Diagnostics GmbH, Mannheim, Germany). After perfusion, a homogeneous liver cell suspension that contained hepatocytes, blood cells, and nonparenchymal cells was obtained by gentle mechanical dispersion and filtering through a 70 µm nylon mesh cell strainer. After centrifugation and resuspension in PBS with 2% fetal calf serum, this preparation was characterized by flow cytometric analysis using a Cytofix/CytoPerm kit (BD PharMingen). Briefly, the cells were stained with one of the following primary antibodies: APC-conjugated mouse anti-human CD45 (BD PharMingen); FITC-, PE-, or APC-conjugated mouse anti-human HLA-ABC (BD PharMingen); or PE-conjugated rat anti-mouse H-2Kd (BD PharMingen). The cells were then washed, fixed, and permeabilized with Cytofix/Cytoperm solution for 20 min. After washing with Perm/Wash buffer twice, cells were incubated with isotype IgG or rabbit anti-human albumin for 30 min at 4°C, followed by incubation with FITC-conjugated donkey anti-rabbit IgG for 30 min at 4°C. After washing with Perm/Wash, the cells were analyzed by flow cytometry.
Fluorescence in situ hybridization (FISH)
Cy3-dUTP-labeled human genome DNA probe and Cy5-dUTP-labeled mouse genome DNA probe were used simultaneously. Slides were heated to 45°C for 30 min, then deparaffinized and dried. Slides were then denatured for 5 min in 2x saline sodium citrate (SSC) buffer, microwaved for 10 min, digested with 0.1% pepsin/0.1M HCl for 5 min, and washed with PBS. After dehydration, probes were applied and sections were incubated at 90°C for 13 min for denaturation. After overnight incubation at 37°C, the sections were stringently washed in 2 x and 1x SSC containing 50% formamide. The nuclei were counterstained with 4',6-diamino-2-phenylindole and multicolored immunofluorescent staining was analyzed by a fluorescence microscope (Leica, Wetzlar, Germany).
Reverse transcription-polymerase chain reaction (RT-PCR)
Mice were anesthetized, then killed by cervical dislocation. Total RNA was extracted from chimeric liver, nontransplanted liver, irradiated liver, human liver, and human CB CD34+ cells using Trizol reagent (Invitrogen Corp., San Diego, CA, USA) according to the manufacturers instructions. Equal amounts of RNA from all samples were subjected to first-strand cDNA synthesis with an oligo dT primer and Superscript II RT (Invitrogen Corp.) The cDNAs were then amplified using an AmpliTaqGold Kit (Applied Biosystems, Foster City, CA, USA) and human-specific primers. Amplification was performed at 95°C for 5–10 min, followed by 30–40 cycles of 94–95°C for 30 s, 56–60°C for 30–60 s, and 72°C for 60 s, with a final extension at 72°C for 7 min. The primers and PCR reaction conditions used are detailed in Table 1
. The PCR products were separated by electrophoresis in 1% agarose gels, stained with ethidium bromide, and photographed.
|
Real-time quantitative RT-PCR analysis
Forward and reverse primers as well as fluorogenic probes were designed according to Perkin-Elmer guidelines (Primer Express Software). Human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) primers and probes were purchased from Applied Biosystems. Quantitative assessment of mRNA expression was performed using a human GAPDH internal standard. The expression of each mRNA was compared with each human liver mRNA expression. The primers and probes are detailed in Table 2
.
|
Statistical analysis
Statistical significance was determined by using the Pearsons correlation coefficient test.
| RESULTS |
|---|
|
|
|---|
cnull mice with purified human CB CD34+ cells and subjected the livers to immunohistochemical analysis at various time points to determine whether the murine livers contain hepatic cells derived from human CB CD34+ cells. Human albumin-expressing cells were invariably found in the livers of all the recipient mice. Some formed large clusters around the portal veins (Fig. 1
|
Because the liver contains a large amount of peripheral blood, we checked the distribution of human peripheral blood cells. Double staining of the liver sections for human CD45 and human albumin revealed small, round, human CD45-positive peripheral blood cells beneath the basal membrane of the portal veins and in the sinusoidal area of the livers (Fig. 1E, F
); an anti-human albumin antibody stained a different population of cells in the same section. We also detected human
-1-antitrypsin-positive cells in the liver (Fig. 1H
), which indicates the functional maturation of human CB-derived hepatocytes; these cells were also present in a section of human liver used as a positive control (Fig. 1G
). These hepatocytes were first detected 1 month after transplantation and tended to increase in number with time (data not shown).
Kupffer cells are spindle-shaped; they are located between hepatocytes and retain macrophage markers such as CD68 (27)
(Fig. 2
A). Mature human Kupffer cells were present in the murine liver environment of the recipient mice (Fig. 2B
). Murine Kupffer cells were not stained by anti-human CD68 antibody (Fig. 2C
).
|
We assessed the ability of human CB CD34+ cells to produce cholangiocytes by immunohistochemistry with antibodies for human mitochondria and c-met. The antibody for c-met is reported to recognize both hepatocytes and cholangiocytes, particularly when they are proliferating (28
, 29)
. Cube-shaped cholangiocytic cells in the recipient livers were positive for human mitochondria and c-met, which suggests that these cells are of human origin (Fig. 2D-F
). Indeed, we identified 250 portal areas from 10 independent mice and found three ducts containing human marker (human mitochondria).
To exclude the possibility that 240cGy radiation might induce liver injury, we evaluated the liver after radiation. Histology showed no liver damages such as inflammation, lobar necrosis, or fibrosis. We could not detect TUNEL (TdT-mediated dUTP-biotin nick end labeling)-positive cells. Furthermore, serum AST/ALT levels did not increase (data not shown).
These results indicate that human CD34+ cells can produce human hepatocytes, Kupffer cells, and cholangiocytes in the murine liver environment; these cells develop even in the absence of massive hepatotoxic damage.
Human albumin is present in the peripheral blood of recipient mice and increases with time after transplantation
To check whether the human albumin-positive cells in the livers of recipient mice have the ability to secrete albumin into the murine bloodstream, we measured levels of human albumin in the blood of recipient mice by ELISA at various points after the transplantation. We could not detect human albumin at all in the peripheral blood of either untransplanted mice (n=5) or mice within 2 months after transplantation (n=5) (Fig. 3
A and data not shown). Serum human albumin was first detected 3 months after transplantation, and the levels increased gradually with time after transplantation. In addition, the human albumin levels increased in all four mice whose levels we measured serially (Fig. 3A
). These results indicate that human CB CD34+ cells can generate human albumin-positive cells continuously in the murine liver and that these cells become mature enough to secrete albumin from their cytoplasm into the bloodstream. Indeed, we found a positive correlation between the frequency of human albumin-positive cells determined by immunohistochemistry and levels of human albumin in the blood of recipient mice (Table 3)
.
|
|
Human albumin levels in the peripheral blood of recipient mice correlate with the degree of peripheral blood chimerism and human T cell frequencies
Using flow cytometry, we detected various types of human hematopoietic cells in the peripheral blood of the recipient mice, including T cells (CD3+, CD4+, CD8+), B cells (CD19+), myelomonocytic cells (CD14+, CD33+), and NK cells (CD56+) (Fig. 3B
and data not shown). This is consistent with previously reports (24
, 25)
. We examined whether the human CB CD34+ cells first give rise to a particular hematopoietic cell population in the peripheral blood and then participate in producing the human cell-derived hepatocytes in the recipient mice. To address this question, we first asked whether the chimerism of the liver in the recipient mice (defined as the levels of human albumin in the serum) correlated with the chimerism of the whole peripheral blood cell population (defined as the percentage of human CD45+ cells relative to all mouse and human CD45+ cells). We found a strong positive correlation between the chimerism of the liver and the whole peripheral blood cell population (Fig. 3C
). We then examined whether the liver chimerism correlated with the percentages of particular types of human leukocytes in the peripheral blood. We found that the percentage of human T cells (human CD3+ cells) most strongly correlated with the levels of human albumin in the serum (Fig. 3D
). The percentage of human myelomonocytic cells [defined as either human CD45+ minus (CD3+ plus CD19+) or human CD14+] correlated weakly with the human albumin levels (Fig. 3D
and data not shown). In contrast, the human albumin levels did not correlate with human B cell (human CD19+) frequency (Fig. 3D
).
Human albumin-positive cells in the livers of recipient mice express both human and mouse markers, suggesting that cell fusion occurs
We next characterized the human hepatocytes and blood cells in the recipient mice by assessing their expression of various surface markers and intracellular proteins by flow cytometry. We first obtained cells from the liver by two-step collagenase perfusion at least 3 months after the transplantation (Fig. 4
A). When the dissociated cells from untransplanted control mice were plotted on the basis of their forward scatter and side scatter, we identified two regions: R1 and R2 (Fig. 4B
). R1 contained mature hepatocytes whereas R2 contained CD45+ hematopoietic cells (data not shown). For the recipient mice, 0.88% to 4.73% of the cells in R1 (mean 2.73%) were positive for human albumin (see R4 in Fig. 4C, D
). These human albumin-positive cells were distinguishable from the human CD45+ hematopoietic cells (see R5 in Fig. 4C
). We confirmed that the human albumin-positive cells and human CD45+ cells expressed human HLA-ABC (Fig. 4E
). Staining with an anti-mouse H-2Kd antibody revealed that the human albumin-positive cells also expressed the murine MHC class I molecule (Fig. 4F
). In contrast, human CD45+ cells in the liver were negative for mouse H-2Kd (Fig. 4G
). These data suggest that the human albumin-positive hepatocytes in this model were produced by cell fusion.
|
The livers of recipient mice contain nucleus positive for both human and mouse genomic DNAs
To clarify the genetic content of the human albumin-positive hepatocytes, we performed FISH for human and mouse genomic DNA. Figure 4H
illustrates the verification of probes on a test specimen. Figure 4I-K
demonstrates detection of human and mouse genomic DNA on the livers of recipient mice, revealing the presence of a single nucleus positive for both human and mouse genome. The percentage of these nuclei ranged from 2 to 5%, similar to the frequency of human albumin-positive cells determined by immunohistochemistry. These data showed that nuclear fusion occurred in the livers of recipient mice.
A wide variety of human liver-specific mRNAs are transcribed in the CB-derived human hepatocytes in the murine liver
We next used RT-PCR to analyze the murine liver for the presence of human albumin mRNAs after human CB CD34+ cell transplantation into liver-intact mice (Fig. 5
A). We first used two different primer pairs to assess the presence of human albumin mRNA, which we detected in the livers of all seven mice transplanted with human CB CD34+ cells. We confirmed that neither the livers of untransplanted mice nor human CB CD34+ cells expressed human albumin mRNA. Human albumin mRNAs were expressed just 1 month after transplantation (data not shown).
|
We then examined the samples for mRNA expression of other human hepatic parenchymal and nonparenchymal markers. To our surprise, we found that a wide variety of human liver-specific mRNAs were newly transcribed: human
-1-antitrypsin (
1AT), transferrin and retinol binding protein 4 (RBP4) and prealbumin (all of which are rapid turnover proteins), carbamoyl phosphate synthetase I (CPSI), CYP3A4, tyrosine aminotransferase (TAT) and tryptophan-2,3-dioxygenase (TO) (all of which serve as terminal hepatic differentiation markers), coagulation factor VIII (FVIII), cytokeratin 7 (CK7), cytokeratin 19 (CK19), and endothelial nitric oxide synthase (eNOS). All of these genes were expressed in the livers of the recipient mice in the absence of any liver damage. We also found that human CK18 mRNA (mature hepatocyte marker; ref. 21
) was newly transcribed in the livers of all seven mice transplanted, although we found that CB CD34+ cells also expressed it (data not shown). It is notable that, as with albumin, the percentage of mice with livers bearing human liver-specific mRNA tended to rise with time after transplantation. Furthermore, using real-time quantitative RT-PCR analysis, we confirmed expression levels of the human albumin, CK7, CPS1, and TAT in chimeric livers (Fig. 5B
). The levels of these genes also tended to rise higher with time after transplantation, and some exceeded 10% compared with those of human livers. These data indicate that human CB CD34+ cells, which are initially destined to become mature blood cells, begin human liver-specific gene transcription in the murine liver through cell fusion.
Human CB CD34+ cells can develop into human albumin-positive hepatocytes whereas CD34– cells cannot
To test whether CD34– cells can develop into mature hepatocytes in the murine liver as CD34+ cells do, we sorted the CB from the same donor into three populations and injected each i.v. into NOD/SCID/
cnull mice: 1) CD34+ cells, 2) CD34–CD14+ cells (monocytes), and 3) CD34–CD14– cells (T cells, B cells, NK cells, mesenchymal stem cells (MSCs), and others). A flow cytometric analysis showed that contamination of the CD34– groups with CD34+ cells was negligible and that the CD14+ and CD14– cells were efficiently separated by cell sorting (Fig. 6
A). Although 2 x 104 CD34+ cells generated large numbers of functional hematopoietic and hepatic cells that expressed human markers, no human albumin expression was detected in the liver at either day 10 or day 110 when 1 x 107 CD34–14+ or CD34–14– cells were transplanted (500-fold the CD34+ cell dose) (Fig. 6B
). In the case of CD34–14– cells transplantation, significant hematopoietic chimerism came from temporarily expanding donor T cells. Indeed, all the hematopoietic cells in these mice are CD3 positive. These results clearly show that only human CB CD34+ cells, and not CD34– cells, can generate human albumin-expressing cells in the livers of recipient mice in our model.
|
| DISCUSSION |
|---|
|
|
|---|
cnull mice show superior efficient human hematopoietic stem cell engraftment (24
-1-antitrypsin protein. In addition, we detected considerable numbers of human albumin-positive cells (an average of 2.73% of the total number of hepatocytes) by flow cytometry. These numbers are close to the numbers detected in the clinical human-to-human transplantation cases. We also detected human albumin in the murine bloodstream. Finally, we revealed that livers of the recipient mice express a variety of human liver-specific genes. These findings suggest that functional human hepatic cells develop in the liver after transplantation of human CB CD34+ cells into liver-intact NOD/SCID/
cnull mice.
Results showing that 1) the human albumin-positive hepatocytes expressed not only human HLA-ABC, but also mouse H-2Kd, and that 2) the livers of recipient mice contained nucleus positive for both human and mouse genomic DNAs strongly support not transdifferentiation, but cell fusion, as the main mechanism of this phenomenon. This appears to contrast with the conclusions drawn from some other human-to-mouse models (16
, 19)
. It is possible that, in our model, the human hematopoietic cells are abundantly supplied from bone marrow to the systemic circulation, and that they infiltrate the liver and have more opportunity to develop into functional human hepatic cells through cell fusion due to the far better human hematopoietic stem cell engraftment.
We found that human albumin levels in the peripheral blood correlated strongly with the overall peripheral blood chimerism and the numbers of human T cells in the peripheral blood, but correlated weakly with the numbers of human myelomonocytic cells in the peripheral blood. However, our short-term and long-term observations revealed that neither CD34–CD14+ cells (monocytes) nor CD34–CD14– cells (T cells, B cells, NK cells, MSCs, and others) could produce albumin-positive cells. This shows that although these terminally differentiated human cells (T cells and myelomonocytic cells) or MSCs may contribute to human liver regeneration indirectly, each alone might be insufficient to become a direct fusion partner. Previous studies have shown that myelomonocytic cells are sufficient for generating hepatocytes in mouse cells (10
, 11)
. Selzner et al. (30)
also proposed that Kupffer cells, which reside in the sinusoids and produce cytokines, recruit other cells or release TNF-
and IL-6, which then initiate hepatocyte proliferation in vivo. Some of our findings support the possibility that myelomonocytic cells or Kupffer cells may to some extent drive the production of human albumin-positive hepatocytes: we detected a weak positive correlation between human myelomonocytic cells and human albumin levels, and detected human CD68+ Kupffer cells in the transplanted murine livers. However, our data showed that 1) human CB CD34–CD14+ cells alone did not develop into human albumin-positive cells, and 2) many of the human albumin-positive cells we detected by immunohistochemistry were not located adjacent to CD68+ Kupffer cells (data not shown). These observations may suggest that the production of human albumin-positive cells, at least in our model, cannot be explained merely by direct cell fusion between myelomonocytic cells/Kupffer cells and hepatocytes, as has been shown in mouse-to-mouse transplantation studies (10
, 11)
. Nevertheless, our experiment cannot exclude the possibility that differentiated progeny of human hematopoietic stem cells fuse with hepatocytes, considering the very long lag time between transplantation of CD34+ cells and the increase in albumin levels. If we transplanted more cells or chose a different mode of transplantation, we could achieve a more efficient deposition of cells in the liver and could detect the fusion of infused human cells. Recently, Manz et al. (31)
showed the prospective isolation of the human clonogenic common myeloid progenitors and their downstream progeny. The transplantation of highly purified hematopoietic intermediates helps us to better understand the ability to fuse them with hepatocytes.
A striking observation from our study is that CB CD34+ cells are transcriptionally converted into liver cells after entering the liver of NOD/SCID/
cnull mice even in the absence of damage-associated stimuli other than a small dose of total body irradiation (with which the mice are preconditioned prior to transplantation). It is generally believed that tissue damage is indispensable for the hematopoietic-to-hepatic cell lineage transition (1)
except for the FAH mouse model (32)
. However, we found that even without massive liver damage, human CB CD34+ cells or their progeny cells could fuse with hepatocytes of NOD/SCID/
cnull mouse, lose their hematopoietic surface markers (CD45), and up-regulate human liver-specific gene transcription, contrary to other human-to-mouse xenogeneic transplantation models (17
, 18
, 20
21
22
23)
. There may be several reasons why a wide variety of human hepatocyte-specific genes are so efficiently transcribed and translated in our liver-intact NOD/SCID/
cnull mouse model. First, the NOD/SCID/
cnull mice may provide murine liver-specific transcription factors that promote human liver-specific gene transcription. It is possible that different strains of xenograft recipients may have different liver environments with respect to liver-specific transcription factors and that these differences influence the efficiency with which human cells with different properties are developed. Second, the observation that human albumin levels in the peripheral blood correlated strongly with human CD3+ T cell levels suggests that these human T cells in murine liver may, not directly but indirectly, induce the hepatocyte development pathway in vivo. Further study is needed to clarify how the transcription of liver-specific genes is up-regulated in nuclei once cells are committed to a hematopoietic lineage. In our model, it took several months to up-regulate mature liver-specific genes. One explanation for the delay in hepatocyte gene activation is that in the case of donor-derived cells emerging around portal veins, cell fusion might have occurred with a progenitor cell, and thus maturation happened slowly.
We transplanted CB CD34+ cells into NOD/SCID/
cnull mice without irradiation but could not observe either hematopoietic engraftment or human hepatocytes in the liver of recipient mice. Therefore, we could not determine the influence of radiation on the frequency of cell fusion. With regard to the human albumin level in the peripheral blood of recipient mice, levels would be expected to be in micrograms per milliliter, not only nanograms per milliliter. Human albumin mRNA levels quantitated by real-time PCR were also low. There seem to be additional factors that control production and secretion of the albumin into the bloodstream of the mice. This awaits further investigation.
Using immunohistochemistry, we also showed that some cholangiocytes express human markers (human mitochondria). Whether this hematopoietic-to-cholangiocytic transition is due to transdifferentiation or cell fusion remains to be elucidated.
In conclusion, we have established a new model of efficient hematopoietic-to-nonhematopoietic transition. This experimental model system allows the formation of relatively large numbers of human-derived hepatic cells under near-physiological conditions, a valuable tool for investigating the development of functional human hepatic cells from hematopoietic cells. Further elucidation of the molecular mechanisms by which blood cells efficiently become liver cells will greatly promote the feasibility of using conventional hematopoietic stem cell transplantation to treat patients with liver dysfunction.
Received for publication March 24, 2006. Accepted for publication May 10, 2007.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. Brezillon, D. Kremsdorf, and M. C. Weiss Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogens Dis. Model. Mech., September 1, 2008; 1(2-3): 113 - 130. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |